USO 21546

TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (AV-951-20-304)

Disease Types: Genitourinary Cancer Research

Available at:

• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Newport News (Port Warwick III)
• Hampton (CarePlex)
• Chesapeake